ArticleThe journal of headache and pain2025

Real-world effectiveness of eptinezumab in chronic migraine-increase in good days in three subgroups: psychiatric comorbidities, prior subcutaneous anti-calcitonin gene-related peptide therapy, and migraine-associated brain fog.

Charles Argoff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.